JP4713698B2 - 疎水性薬剤の処方 - Google Patents

疎水性薬剤の処方 Download PDF

Info

Publication number
JP4713698B2
JP4713698B2 JP53869898A JP53869898A JP4713698B2 JP 4713698 B2 JP4713698 B2 JP 4713698B2 JP 53869898 A JP53869898 A JP 53869898A JP 53869898 A JP53869898 A JP 53869898A JP 4713698 B2 JP4713698 B2 JP 4713698B2
Authority
JP
Japan
Prior art keywords
formulation
indolinone
group
compounds
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP53869898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001514626A5 (enExample
JP2001514626A (ja
Inventor
シェノイ，ナーマーダ
ワグナー，グレゴリー・エス
Original Assignee
スージェン， インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スージェン， インク． filed Critical スージェン， インク．
Publication of JP2001514626A publication Critical patent/JP2001514626A/ja
Publication of JP2001514626A5 publication Critical patent/JP2001514626A5/ja
Application granted granted Critical
Publication of JP4713698B2 publication Critical patent/JP4713698B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
JP53869898A 1997-03-05 1998-03-04 疎水性薬剤の処方 Expired - Fee Related JP4713698B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3987097P 1997-03-05 1997-03-05
US60/039,870 1997-03-05
US4125197P 1997-03-18 1997-03-18
US60/041,251 1997-03-18
PCT/US1998/004134 WO1998038984A2 (en) 1997-03-05 1998-03-04 Formulations for hydrophobic pharmaceutical agents

Publications (3)

Publication Number Publication Date
JP2001514626A JP2001514626A (ja) 2001-09-11
JP2001514626A5 JP2001514626A5 (enExample) 2005-07-14
JP4713698B2 true JP4713698B2 (ja) 2011-06-29

Family

ID=26716539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53869898A Expired - Fee Related JP4713698B2 (ja) 1997-03-05 1998-03-04 疎水性薬剤の処方

Country Status (10)

Country Link
US (2) US6248771B1 (enExample)
EP (1) EP1014953B1 (enExample)
JP (1) JP4713698B2 (enExample)
AT (1) ATE554750T1 (enExample)
AU (1) AU743024B2 (enExample)
CA (1) CA2282439C (enExample)
CO (1) CO4940469A1 (enExample)
ES (1) ES2384551T3 (enExample)
NZ (1) NZ510991A (enExample)
WO (1) WO1998038984A2 (enExample)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US6846839B1 (en) 1995-06-07 2005-01-25 Sugen, Inc. Methods for treating diseases and disorders related to unregulated angiogenesis and/or vasculogenesis
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6235769B1 (en) 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6569868B2 (en) 1998-04-16 2003-05-27 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
DK2020408T3 (da) 1998-05-29 2013-09-30 Sugen Inc Pyrrol-substitueret 2-indolinon som proteinkinaseinhibitor
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000056338A1 (en) * 1999-03-19 2000-09-28 Parker Hughes Institute Quinazoline formulations and therapeutic use thereof
US7064114B2 (en) 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
EP1169054B1 (en) * 1999-04-09 2004-08-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Prognosis of ptp lar related diseases
ES2292461T3 (es) * 1999-07-07 2008-03-16 Astrazeneca Uk Limited Derivados de quinazolina.
GB9925127D0 (en) * 1999-10-22 1999-12-22 Pharmacia & Upjohn Spa Oral formulations for anti-tumor compounds
US6878733B1 (en) 1999-11-24 2005-04-12 Sugen, Inc. Formulations for pharmaceutical agents ionizable as free acids or free bases
DE60030164T2 (de) * 1999-12-30 2007-08-30 Sugen, Inc., San Francisco 3-Heteroarylidenyl-2-Indolinon Derivate für die Modulierung der Aktivität einer Proteinkinase und für die Verwendung bei der Chemotherapie von Krebs
PT1255752E (pt) 2000-02-15 2007-10-17 Pharmacia & Upjohn Co Llc Inibidores de proteína quinases: 2-indolinonas substituídas com pirrolo
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1294688A2 (en) 2000-06-02 2003-03-26 Sugen, Inc. Indolinone derivatives as protein kinase/phosphatase inhibitors
WO2002000644A1 (en) 2000-06-24 2002-01-03 Astrazeneca Ab Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases
AU2002216758A1 (en) * 2000-07-03 2002-01-14 Astrazeneca Ab Quinazolines with therapeutic use
AU7709901A (en) * 2000-07-24 2002-02-05 Upjohn Co Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilicdrugs
WO2002013762A2 (en) * 2000-08-10 2002-02-21 Delsys Pharmaceutical Corporation Improved solid pharmaceutical dosage formulation of hydrophobic drugs
WO2002030466A2 (en) * 2000-10-11 2002-04-18 Purdue Research Foundation Pharmaceutical applications of hydrotropic agents, polymers thereof, and hydrogels thereof
US20050158271A1 (en) * 2000-10-11 2005-07-21 Lee Sang C. Pharmaceutical applications of hydrotropic polymer micelles
AR042586A1 (es) 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
WO2002069936A2 (en) * 2001-03-02 2002-09-12 Dr. Reddy's Laboratories Ltd. Pharmaceutical composition of ibuprofen
US6912582B2 (en) 2001-03-30 2005-06-28 Microsoft Corporation Service routing and web integration in a distributed multi-site user authentication system
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
BR0214357A (pt) * 2001-11-21 2004-09-14 Sugen Inc Formulações farmacêuticas compreendendo derivados de indolinona
US6797825B2 (en) 2001-12-13 2004-09-28 Abbott Laboratories Protein kinase inhibitors
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US20030139386A1 (en) * 2001-12-21 2003-07-24 Sophie Cote Pharmaceutical compositions based on azetidine derivatives
KR20040085151A (ko) * 2002-01-17 2004-10-07 뉴로젠 코포레이션 캡사이신 조절자로서의 치환된 퀴나졸린-4-일 아민 유사체
MXPA04006992A (es) * 2002-02-15 2004-11-10 Upjohn Co Procedimiento para preparar derivados de indolinona.
IL163642A0 (en) * 2002-02-26 2005-12-18 Astrazeneca Ab Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
US8299108B2 (en) * 2002-03-29 2012-10-30 Novartis Ag Substituted benzazoles and methods of their use as inhibitors of raf kinase
EA007987B1 (ru) * 2002-03-29 2007-02-27 Чирон Корпорейшн Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
MXPA04010539A (es) 2002-04-26 2005-01-25 Nippon Shinyaku Co Ltd Derivados de quinazolina y medicamentos que los contienen.
KR20050084292A (ko) * 2002-12-13 2005-08-26 뉴로젠 코포레이션 캅사이신 수용체 조절체로서 2-치환된 퀴나졸린-4-일아민동족체
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
WO2004087153A2 (en) * 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
WO2004091625A1 (en) 2003-04-16 2004-10-28 F. Hoffmann-La Roche Ag (6-(phenoxy)-pyrido`3,4-d! pyrimidin-2-yl)-amine derivatives as p38 kinase inhibitors for the treatment of inflammatoryy conditions such as rheumatois artritis
MXPA05011103A (es) 2003-04-16 2005-12-12 Hoffmann La Roche Compuestos de quinazolina.
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
ES2327418T3 (es) * 2003-10-16 2009-10-29 Novartis Vaccines And Diagnostics, Inc. Benzazoles sustituidos y uso de los mismos como inhibidores de la quinasa raf.
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7491263B2 (en) 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
EP1746999B1 (en) 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
CA2569763C (en) 2004-06-08 2013-03-12 Decode Chemistry, Inc. 2,4-diaminoquinazolines for spinal muscular atrophy
RU2382034C2 (ru) * 2004-11-09 2010-02-20 Ф.Хоффманн-Ля Рош Аг Соединения аминохиназолинов
DE602005026865D1 (de) 2004-12-14 2011-04-21 Astrazeneca Ab Pyrazolopyrimidinverbindungen als antitumormittel
US8673351B2 (en) * 2005-03-21 2014-03-18 Ivax Pharmaceuticals S.R.O. Crystallization inhibitor and its use in gelatin capsules
EP1928861B1 (en) 2005-09-20 2010-11-17 AstraZeneca AB 4- (ih-indazol-5-yl-amino)-quinazoline compounds as erbb receptor tyrosine kinase inhibitors for the treatment of cancer
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
US20070167422A1 (en) * 2006-01-18 2007-07-19 Yu Kwok S Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
JP2009528365A (ja) * 2006-02-28 2009-08-06 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン及びキナゾリン誘導体
WO2008016973A1 (en) 2006-08-01 2008-02-07 Families Of Spinal Muscular Atrophy 2,4-diaminoquinazolines for spinal muscular atrophy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EP2200613B1 (en) 2007-09-21 2018-09-05 The Johns Hopkins University Phenazine derivatives and uses thereof
EP2245026B1 (de) 2008-02-07 2012-08-01 Boehringer Ingelheim International GmbH Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2009114365A2 (en) * 2008-03-13 2009-09-17 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
AU2009247782C1 (en) 2008-05-13 2013-09-19 Astrazeneca Ab Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (N-methylcarbamoylmethyl) piperidin- 4-yl] oxy } quinazoline
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP5359333B2 (ja) * 2009-02-05 2013-12-04 ゼリア新薬工業株式会社 コロソリン酸含有水性液剤
PL2401267T3 (pl) * 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
EP3575288B1 (en) 2009-09-03 2021-10-27 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
ES2727733T3 (es) * 2009-11-10 2019-10-18 Celgene Corp Nanosuspensión de un fármaco poco soluble preparada por el proceso de microfluidización
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
CN102716103B (zh) * 2012-07-02 2013-12-18 西安力邦制药有限公司 2,2′,6,6′-四异丙基-4,4′-二联苯酚软胶囊制剂及其制备方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
CN103837615B (zh) * 2014-02-15 2015-05-20 青岛农业大学 一种应用高效液相色谱法同时测定植物蜕皮激素类物质的方法
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2016205423A2 (en) 2015-06-15 2016-12-22 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CA3180971A1 (en) * 2020-04-22 2021-10-28 Scienture, Inc. Long-acting bupivacaine microsphere formulations
CN113398067B (zh) * 2021-07-19 2022-08-16 宁波三生生物科技股份有限公司 一种四烯雌酮注射液及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970725A (en) 1972-09-26 1976-07-20 Dai Nippon Toryo Co., Ltd. Powdery coating composition and process for preparing the same
US3850939A (en) 1973-02-20 1974-11-26 Parke Davis & Co 5-nitro-2-thiazolylthiopyridine,1-oxides
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
JPS59190967A (ja) * 1983-04-15 1984-10-29 Hokuriku Seiyaku Co Ltd １−（２，６−ジフルオロフエニル）−２−インドリノン誘導体
JPS61167616A (ja) * 1985-01-22 1986-07-29 Adeka Argus Chem Co Ltd 放射線増感剤
EP0448841B1 (en) 1990-03-19 1993-06-02 Agfa-Gevaert N.V. Photographic materials containing electron accepting agents
EP0548250B1 (en) 1990-09-10 1996-03-27 Rhone-Poulenc Rorer International (Holdings) Inc. Substituted bicyclic aryl compounds exhibiting selective leukotriene b4 antagonist activity
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
JPH11507052A (ja) * 1995-06-07 1999-06-22 スージェン・インコーポレーテッド キナゾリンおよび医薬組成物
WO1996040113A2 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Phosphatase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5763470A (en) * 1995-06-07 1998-06-09 Sugen Inc. Benzopyran compounds and methods for their use
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity

Also Published As

Publication number Publication date
ATE554750T1 (de) 2012-05-15
WO1998038984A3 (en) 1999-01-28
CO4940469A1 (es) 2000-07-24
US6696482B2 (en) 2004-02-24
ES2384551T3 (es) 2012-07-06
US20010012844A1 (en) 2001-08-09
US6248771B1 (en) 2001-06-19
HK1028548A1 (en) 2001-02-23
NZ510991A (en) 2002-11-26
AU743024B2 (en) 2002-01-17
WO1998038984A2 (en) 1998-09-11
EP1014953A2 (en) 2000-07-05
JP2001514626A (ja) 2001-09-11
CA2282439C (en) 2010-05-04
AU6680698A (en) 1998-09-22
CA2282439A1 (en) 1998-09-11
EP1014953B1 (en) 2012-04-25

Similar Documents

Publication Publication Date Title
JP4713698B2 (ja) 疎水性薬剤の処方
EP1233943B1 (en) Ionizable indolinone derivatives and their use as ptk ligands
KR20180088460A (ko) 악성종양의 치료 방법
WO2012154760A1 (en) Fused heterocyclic compounds as sodium channel modulators
US20240041835A1 (en) Pharmaceutical composition
US6878733B1 (en) Formulations for pharmaceutical agents ionizable as free acids or free bases
EP2819998B1 (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride
US9353067B2 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US6492530B1 (en) Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
AU770904B2 (en) Formulations for hydrophobic pharmaceutical agents
WO2019042187A1 (zh) 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
NZ521773A (en) Use of formulations for hydrophobic pharmaceutical agents in treatment or prevention of cell proliferative disorders
US10966964B2 (en) Method for preparing pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound
HK1028548B (en) Formulations for hydrophobic pharmaceutical agents
WO2019001307A1 (zh) 一种酰胺类化合物及包含该化合物的组合物及其用途
US20250120981A1 (en) Mrtx1133 pharmaceutical compositions
US11834469B2 (en) AMP-activated protein kinase activating compounds and uses thereof
US20190054073A1 (en) Pharmaceutical composition comprising pyrrolo-fused six-membered heterocyclic compound
KR101770014B1 (ko) 아미노벤조산 유도체의 유기 아민염 및 그 제조 방법
US8222284B2 (en) Stable formulations of thiadiazole derivative
TW202421150A (zh) 艾魯美冷之分散體
KR20240142398A (ko) 암을 치료하는데 사용하기 위한 치환된 피리미딘-4(3h)-온
HK40102115A (en) Pharmaceutical composition for treating leukemia comprising flt3 inhibitor
HK1204475B (en) Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041110

A72 Notification of change in name of applicant

Free format text: JAPANESE INTERMEDIATE CODE: A721

Effective date: 20071112

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20071130

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20071130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080826

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080903

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090123

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090225

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20091020

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20091020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100309

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100708

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110124

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110325

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees